eli lilly Tirzepatide: Authorisation Holder, Brand Names And Verification

By What Peptides Editorial Team · Updated 2026-09-14 · Part of Peptide Research, Industry Updates & Practical Guides

Company names attached to medicines carry a specific legal meaning that is easy to miss. A marketing authorisation holder is the entity that holds the approval and answers to the regulator for the product, and that name appears in the public record. eli lilly is the holder associated with tirzepatide in the jurisdictions where the medicine has been authorised, and tirzepatide itself is a 39-residue peptide acting on both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This page explains what the holder role covers, how branded, generic and compounded products are registered, and how to confirm all of it on an official register.

This page is for research and educational reference only, not medical advice. It reports regulatory structure, not recommendations, and it describes no product as available from any source. The reader's own national regulator is the authority for what is authorised in their country. The peptide research and industry updates hub carries related material. where tirzepatide announcements come from and authorised presentations and oral formulation research cover adjacent questions, while how naming conventions are handled in the science cluster explains why one molecule can appear under several names.

What A Marketing Authorisation Holder Is

The marketing authorisation holder is the company or entity in whose name an authorisation is granted. It holds the legal right to place the product on the market in that jurisdiction, and it carries the obligations that come with it: maintaining the product information, reporting suspected adverse reactions, submitting variations when anything changes, and answering to the regulator. The holder is not always the same entity as the manufacturer of the active substance or of the finished product, and the product information usually names each site separately. Confusing the two is a common error in secondary writing about medicines.

For tirzepatide, the holder named in the jurisdictions where the medicine has been authorised is eli lilly, and the active substance is a 39-residue peptide with agonist activity at both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Those two facts sit in different fields of the same record. The holder field tells you who is answerable for the product. The substance field tells you what the molecule is. Neither field tells you what is authorised in a country you have not checked, because authorisations are national or regional rather than global.

How Brand, Generic And Compounded Entries Differ

A branded entry results from a full application containing quality, non-clinical and clinical data assessed by the regulator, and it is granted to a named holder under an invented name. A generic entry relies on the reference product's data together with demonstrated equivalence, and it can only be authorised after the reference product's data and market protections have expired. There is no generic entry merely because a molecule is well known: each one is a separate decision with its own date and its own assessment. Compounded preparations are not entered on the register at all, because they are not authorised as products. The register is therefore the wrong place to look for one, and the pharmacy licence record is the right one.

The practical consequence is that three very differently regulated things can be described with similar words. A branded pack carries an approved leaflet and a product information document. A generic pack carries its own versions of both, referencing the originator's data. A compounded preparation carries a pharmacy label and no approved product information of its own, and it is overseen as pharmacy practice rather than as a product. A reader who does not know which of the three they are looking at cannot reason correctly about what checks were applied to it, or about who carries responsibility for it afterwards.

• A branded entry follows a full application assessed by the regulator and is granted to a named holder.
• A generic entry relies on demonstrated equivalence and can only be authorised after protections expire.
• No generic entry exists automatically; each one is a separate regulatory decision with its own date.
• Compounded preparations are not authorised products and hold no register entry of their own.
• Only the authorised product carries an approved product information document and leaflet.

Verifying The Record Yourself

Verification is a short sequence and it uses only public documents. Search the national medicines register for the active substance rather than for a company or trade name, because one substance can sit under several invented names and one company can hold many authorisations. Open each entry and read the product information: it names the holder, the presentations, the strengths and the authorised route of administration. Note the date of the last revision. An entry that is several years old may predate a variation, so check whether a later version of the document has been published.

Then check the two surrounding pages. The regulator's compounding pages state whether any allowance currently applies to the substance in your jurisdiction, and any shortage listing supporting such an allowance will be dated. The safety alert and recall pages list notices issued against the name. Finally, compare the result with the labelling in front of you: holder name, presentation and strength format should all match an entry. Where they do not, the discrepancy is worth raising with the regulator rather than resolving by assumption. A verified match is worth recording, because both labels and shortage listings change.

This page is part of the Peptide Research, Industry Updates & Practical Guides guide.